Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A study by CU Cancer Center researcher Joaquin Espinosa and his team discovered that oxygen deprivation initially suppresses tumor growth, but later promotes metastasis. The researchers hope to develop therapies targeting specific processes in cancer cells at different stages of hypoxia.
A cohort study of 672 cancer patients found a cumulative incidence of venous thromboembolism at 12.9% and arterial thromboses at 1.8%. This risk appears to be independent of underlying cancer type or immune checkpoint inhibitor used.
Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.
New research from the University of East Anglia reveals comorbidities such as heart disease, respiratory disease, and obesity increase mortality rates in COVID-19 patients. Blood pressure medications found to be protective against severe outcomes.
The funding supports development of a new drug testing platform to predict treatment outcomes for patients with cancer. Researchers will leverage tissue bioengineering advances and genomic technologies to reconstruct and grow patient-derived tumor organoids in the presence of different drugs.
Researchers at VCU Massey Cancer Center developed a bespoke therapy combining phenformin and AZD3965 to exploit the metabolic 'hunger' of aggressive neuroblastoma, leading to greater tumor shrinkage without collateral damage. The treatment showed promising results in mice seeded with MYCN-amplified neuroblastoma patient cells.
Researchers at Hokkaido University developed a hydrogel that rapidly reprograms differentiated cancer cells into cancer stem cells within 24 hours. The study has significant implications for developing targeted anti-cancer therapies and personalized medicines by targeting cancer stem cells, which are resistant to current treatments.
Oak Ridge National Laboratory (ORNL) has produced a key radioisotope, actinium-225 nitrate, for pharmaceutical companies developing new cancer treatments. ORNL's production of Ac-225 enables the support of applications without disclosing proprietary information, fulfilling FDA requirements.
Researchers used an FDA-approved cancer drug to blunt the effects of a toxic COVID-19 viral protein on human cells. The study found that the drug improved cell survival by 12% and restored damaged cellular functions.
A new study reveals that patients with newly diagnosed incurable cancer experience significant physical and emotional distress, including anxiety and depression. Comprehensive palliative care services are essential to address these needs and improve quality of life for patients.
Researchers from Queen Mary University of London developed a machine learning algorithm that ranks cancer drugs based on their effectiveness in reducing cancer cell growth. The approach has the potential to advance personalized therapies by allowing oncologists to select the best drugs for individual patients.
A new study found that a second drug targeting KRASG12C showed promising results in treating non-small-cell lung cancer (NSCLC) with this specific mutation. Nearly half of patients evaluable for clinical activity had a partial response to treatment, setting up potential future trials and combinations.
Studies found that disrupting interaction between p53 and Mdm2 in tumor cells is less effective than thought, as it can impair immune cell function. New compound APG115 showed promise in boosting T cell activity against cancer, suggesting a potential therapeutic approach.
A recent survey of nearly 7,500 physicians globally found that burnout has reached a very high rate, with women in healthcare suffering the most. The COVID-19 pandemic has exacerbated this issue, and policymakers must work with the scientific community to develop a comprehensive burnout prevention strategy.
Exposure to hydroxyprogesterone caproate during pregnancy has been linked to a higher risk of early-onset cancer in offspring, particularly colorectal and prostate cancers. The study found that adult children of mothers who received the drug had more than twice the odds of cancer.
Researchers at Boston University School of Medicine have found that PXS-LOX_1 and PXS-LOX_2 can slow primary myelofibrosis's disease progression in experimental models by inhibiting lysyl oxidase. These findings represent a possible novel avenue for treatment, potentially slowing cancer progression and easing symptoms.
Researchers have developed a nondestructive way to measure drug treatment responses in lab-grown cancer samples using redox imaging. The technique allows for sensitive information about drug responsiveness and can identify organoid subpopulations with distinct responses.
Researchers found that ibuprofen inhibits the alternative splicing event generating RAC1B, overexpressed in BRAF-mutated colorectal tumors. Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein kinase complex, promoting nuclear exclusion of SRPK1 and SRSF1.
Endogenous Cushing's syndrome is associated with a threefold increase in death, primarily due to cardiovascular disease and infections. The study analyzed data from over 19,000 patients and found that mortality rates were lower after 2000, but still unacceptably high.
A recent study published by The Endocrine Society has found that commonly used medications for type 2 diabetes and obesity, known as GLP-1 RAs, are not associated with an increased risk of breast cancer. This new research provides relief to concerns arising from previous clinical trials of liraglutide.
Researchers have identified a small molecule drug candidate that targets the uptake of glutamine in cancer cells, slowing the growth of melanoma and other cancers. The study, published in Molecular Cancer Therapeutics, offers an exciting new therapeutic approach for treating tumors addicted to glutamine.
The LSU Veterinary School has received a $11 million grant from the National Institutes of Health to create a Center for Pre-Clinical Cancer Research, which aims to develop more effective anti-cancer treatments. The new center will provide specialized core facilities and training opportunities for researchers.
Scientists at Karolinska Institutet have determined the 3D structure and mechanism of MGST2, an enzyme involved in oxidative stress and DNA damage. The study's findings reveal three functional units controlled by sophisticated movements, regulating vital functions and offering insights into future drug development.
Scientists at Tokyo Medical and Dental University identified a combination of pitavastatin and capmatinib as effective in inhibiting oral cancer cell growth. This breakthrough provides new hope for treating devastating diseases like esophageal carcinoma, which has no targeted therapies.
Researchers discovered that varying levels of a DNA repair enzyme called AAG can lead to different outcomes after exposure to NDMA, a probable carcinogen. High levels of AAG can cause tissue damage and cell death, while low levels can result in more cancer mutations.
A new grant will enable researcher Neil Box to conduct further follow-up work with a longitudinal study of mole development in kids, aiming to determine the effects of early sun exposure. The study aims to develop more sophisticated measures of sun damage and explore its relationship with melanoma risk.
Researchers at Duke-NUS Medical School and A*STAR discovered that inhibiting the Wnt signalling pathway with ETC-159 can reverse PARP inhibitor resistance in several cancer cell lines. This breakthrough could lead to novel anti-cancer treatments for cancers with overactive Wnt signalling, such as colorectal cancer.
Researchers will explore the impact of COVID-19 on blood sugar management in children with type 1 diabetes and obesity. Emerging studies will examine the implications for individuals with high blood sugar levels, adrenal insufficiency, and vitamin D deficiency.
A Northwestern University team developed an experimental drug that crosses the blood-brain barrier and triggers death of tumor cells. The spherical nucleic acid (SNA) drug has shown promise for treating other neurological diseases like Alzheimer's and Parkinson's.
The CCE-DART project aims to develop interconnected tools to reduce the complexity of investigator-initiated trials, incorporating cutting-edge digital technologies. It will harmonize molecular multi-tier profiling platforms to precisely match patients to novel anti-cancer medicines based on genetic tumor specificities.
Researchers at Hebrew University have developed human-on-a-chip technology that allows for real-time monitoring of drug treatments in humans. The technology has the potential to significantly reduce testing and production time for drugs, saving time, money, and unnecessary suffering.
Researchers developed a tumor-penetrating peptide that can deliver chemotherapy drugs deep into pancreatic cancer tumors, increasing effectiveness and reducing metastasis. The therapy showed promising results in animal models, with significant increases in survival and reductions in cancer spread.
A new study found that global clinical trials enrolled less than half the proportion of Black patients as U.S. trials, highlighting a trend that may exacerbate racial disparities in cancer research and care. The study suggests that globalization of cancer clinical trials may be a key driver of these disparities.
A study found that night shifts disrupt natural rhythms in cancer-related genes, making workers more vulnerable to DNA damage. This can lead to increased cancer risk, and researchers hope to develop prevention strategies and treatment options to address this issue.
Researchers have developed a new inhibitor that targets the multi-drug resistant protein 4 (MRP4), blocking its transport of cancer-promoting messengers and allowing chemotherapy to work again. This could improve treatment options for persistent cancers.
Cancers resistant to radiotherapy may be rendered susceptible through immunotherapy treatment, according to a new study. The research found that profiling the immune landscape of cancers before therapy can identify patients who are likely to respond well or poorly to radiotherapy.
Researchers at Lund University have developed a new method for generating antibodies using CRISPR-Cas9, which enables the identification of novel target molecules and could lead to more effective treatments for cancer and autoimmune diseases.
A new study found that cancer survivors who walked at a slow pace had a significantly increased risk of death from any cause, with the association holding for nine cancer types. The researchers call for more research into targeted interventions to improve walking ability and increase survival among cancer patients.
Scientists have isolated a peptide, EnnA, from a fungus in Morocco that directly inhibits HSP90, a powerful cell protector hijacked by cancer. Early evidence shows EnnA induces immune cells to attack cancer cells, promoting immunogenic cell death and potentially offering a new treatment for triple negative breast cancer.
Researchers at Baylor College of Medicine identified proteomic signatures associated with aggressive cancer types, including altered cellular pathways and novel therapeutic targets. The study provided proof-of-concept that proteomics analysis is a valuable strategy to identify potential therapeutic targets.
Researchers have created a boron-containing chemical group that is 10,000 times more stable than its predecessors. This new group, called benzoxaboralone, can be added to compounds to provide desirable attributes such as improved protein-binding strength.
Researchers have discovered that malignant rhabdoid tumour (MRT) arises from developmental cells in the neural crest whose maturation is blocked by a genetic defect. The study identified two drugs that could be used to overcome this block and resume normal development, bringing hope for new treatments.
Researchers at Hong Kong Baptist University develop a peptide-linked drug targeting two viral proteins produced by Epstein-Barr virus, reducing cancer cell damage and increasing drug uptake rates. The novel drug has shown efficacy in animal models and is being further developed for clinical trials.
Researchers develop targeted immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented on the cell surface. The therapy uses bispecific antibodies to recognize and destroy cancer cells, bypassing conventional antibody limitations.
Scientists have identified a region within the GLI1 gene responsible for regulating its expression, providing a potential target for cancer treatment. Removing this region eliminates GLI1 activity, halting excessive cell division characteristic of cancer.
Researchers identified various molecular pathways and predictive biomarkers of drug resistance in diffuse large B-cell lymphoma. Tailored therapies can improve prognosis for patients with refractory disease, particularly those with specific clinical features.
Researchers discovered artificial microswimmers slow down and accumulate in low-fuel regions where their speed is minimized. This finding suggests a new strategy to improve targeted cancer therapy by delivering chemotherapy drugs to the most problematic cells.
Researchers developed polymeric nano-micelles that target specific levels of c-Myc expression, a key factor in cancer cell proliferation. The study showed varying efficacy depending on tumor c-Myc expression levels, with higher expression associated with better antitumor activity.
A study by the Mays Cancer Center at UT Health San Antonio found that bladder cancer is more advanced and deadly in South Texas residents than in many parts of the country. The disease disproportionately affects Latinos and women, with worse survival rates regardless of geographic location.
The ESMO Targeted Anticancer Therapies Congress 2021 presented new data on drug discovery and development for a range of targets, including precision medicine. World-renowned experts discussed breakthroughs in the microbiome and oncolytic viruses, highlighting their potential as tools and targets.
A new study by Yale Cancer Center found sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. The findings suggest a possible new approach in the prevention and treatment of endometrial cancer recurrence, which is currently being evaluated in a multi-center trial.
A recent study found that MYCN overexpression leads to increased iron levels, which induce ferroptosis, a type of cell death. This vulnerability can be exploited by drugs blocking ROS elimination, making cancer cells susceptible to treatment. The researchers plan to test FDA-approved rheumatoid arthritis drugs in preclinical models.
NYUAD researchers have developed a new technology that enables the creation of high throughput arrays of miniaturized 3D tumor models, which can be safely cryopreserved and stored for on-demand drug testing use. This technology has the potential to revolutionize personalized medicine by predicting the outcomes of drug efficacy.
The study demonstrates MEK inhibitors as a promising targeted therapy for basal subtype bladder cancer, highlighting the importance of 3D cell culture drug screening. Established genomic and transcriptomic data are correlated with drug response to identify novel groups of tumors vulnerable to specific drugs.
Scientists at the University of Cambridge have identified a potential new treatment to protect immunosuppressed transplant patients from HCMV reactivation, which can cause serious illness and death. The 'shock and kill' treatment strategy uses epigenetic inhibitors to expose and destroy dormant HCMV infections.
Researchers have found that short strands of cell-free DNA in urine can indicate a difference between healthy individuals and those with cancer. The DNA fragments are protected from degradation and can provide meaningful information about disease complexity like cancer.
Researchers have used a new technique to track the reaction of Osmium in single lung cancer cells, providing crucial insights into potential cellular targets for new cancer treatments. The findings could lead to the development of sustainable and effective treatments using Osmium as a catalyst.
Researchers at Medical University of Vienna have found a previously unknown molecular connection between an inflammatory signalling molecule and one of the main oncogenes, c-Myc. This interaction causes slower degradation of c-Myc, leading to higher cell division rates and resistance to chemotherapeutics.
A study by the University of Zurich found that 63% of drugs with rebates granted in Switzerland have low clinical benefits, while 49% have no significant benefit. The research highlights the need for transparent cooperation between European countries to improve drug pricing and patient access.
The article discusses the relationship between DNA repair pathways and cancer cells, highlighting five critical pathways and their impact on cancer evolution. The review suggests potential clinical interventions to address pathway damage, offering new insights into cancer treatment.